[go: up one dir, main page]

Amberla et al., 1996 - Google Patents

669 Tau levels in CSF are related to cognitive functions in familial Alzheimer's disease

Amberla et al., 1996

Document ID
10787509776885349430
Author
Amberla K
Ahnkvist O
Basun H
Jensen M
Viitanen M
Wahlund L
Lannfelt L
Publication year
Publication venue
Neurobiology of Aging

External Links

Continue reading at scholar.google.com (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—G01N2333/4701
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/564—Immunoassay; Biospecific binding assay for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis

Similar Documents

Publication Publication Date Title
McLean et al. Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease
Sjögren et al. Decreased CSF-β-amyloid 42 in Alzheimer’s disease and amyotrophic lateral sclerosis may reflect mismetabolism of β-amyloid induced by disparate mechanisms
US5270165A (en) Method of diagnosis of amyloidoses
Sjögren et al. Both total and phosphorylated tau are increased in Alzheimer's disease
JP5247963B2 (en) Diagnosis of tauopathy
Ronald et al. Consensus report of the working group on:“Molecular and biochemical markers of Alzheimer’s disease”
Ghanbari et al. Biochemical assay for AD7C‐NTP in urine as an Alzheimer's disease marker
Skoog et al. A population-based study of tau protein and ubiquitin in cerebrospinal fluid in 85-year-olds: relation to severity of dementia and cerebral atrophy, but not to the apolipoprotein E4 allele
JP5687332B2 (en) Prescription for diagnosis of Alzheimer's disease
JP2004527754A (en) Differential diagnostic processing of Alzheimer's dementia and apparatus therefor
WO1992000521A1 (en) Diagnostic and prognostic methods based on soluble derivatives of the beta amyloid protein precursor
Wang et al. Synaptic vesicle glycoprotein 2 A in serum is an ideal biomarker for early diagnosis of Alzheimer’s disease
Blennow et al. Combination of the different biological markers for increasing specificity of in vivo Alzheimer’s testing
Yamada et al. Increased concentration of C4d complement protein in the cerebrospinal fluids in progressive supranuclear palsy
Kalman et al. Serum and cerebrospinal fluid cystatin C levels in vascular and Alzheimer's dementia
EP1370870A2 (en) Diagnostic screens for alzheimer's disease
Amberla et al. 669 Tau levels in CSF are related to cognitive functions in familial Alzheimer's disease
US8377640B2 (en) Diagnostic screens for Alzheimer's disease
Molina et al. 667 Detection of tau proteins in cerebrospinal fluids from Alzheimer's patients
Arai et al. 666 Microtubule-associated protein tau in cerebrospinal fluid: Implications for a potential diagnostic marker in Alzheimer's disease
Akatsu et al. 668 Characterization of tau in cerebrospinal fluids (CSF) of neuropathological confirmed Alzheimer cases
Andreasen et al. 671 A community-based follow-up study on CSFtau protein in patients with dementia
Blomberg et al. 670 Increase of CSF tau levels in most Alzheimer patients during 15 months follow-up
Younkin et al. 673 Analysis of plasma Aβ concentration in sporadic AD patients and non-demented subjects of all ages
KR102478021B1 (en) Diagnosis of Alzheimer's disease Using Plasma